Plaque Psoriasis

Treatment with halobetasol propionate foam improved plaque psoriasis in adolescent patients, according to a study presented at the South Beach Symposium Medical Dermatology Summit.

An investigational new drug program has been approved by the FDA for oral orismilast for the treatment of plaque psoriasis, Union Therapeutics announced in a press release.

Risankizumab was associated with significant improvement over ustekinumab and placebo in a number of quality-of-life parameters in a cohort of patients with psoriasis, according to a study.

Bimekizumab showed evidence of superior skin clearance in patients with plaque psoriasis compared with adalimumab, according to a presentation at the European Academy of Dermatology and Venereology virtual congress.

Sonelokinab showed efficacy through 24 weeks of treatment in moderate to severe plaque psoriasis, according to phase 2b study results presented at the European Academy of Dermatology and Venereology virtual congress.

Tremfya has shown high rates of long-term skin clearance in patients with moderate to severe plaque psoriasis in a phase 3 extension study, Janssen Pharmaceutical Companies announced in a press release.

A twice-weekly dose of topical calcipotriene and betamethasone dipropionate increased the time in plaque psoriasis remission in the phase 3 PSO-LONG trial, according to a study published in Journal of the American Academy of Dermatology.

A biologics license application for bimekizumab has been accepted by the FDA for the treatment of adults with moderate to severe plaque psoriasis, according to a press release.

Tildrakizumab was efficacious and safe in treating plaque psoriasis over 4 years, according to a study presented at the American Academy of Dermatology virtual meeting.

Tapinarof cream showed positive results in treating plaque psoriasis in two phase 3 clinical trials, Dermavant Sciences announced in a press release.